Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is an electrolyte solution presented as a sterile solution for extracorporeal use. It provides calcium ions to correct calcium deficiency and support electrolyte balance in patients requiring intravenous supplementation. It is commonly employed in critical care settings, such as surgery and intensive care units, where rapid calcium repletion is essential.

GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions.

Icalziss is used to manage conditions associated with calcium deficiency and electrolyte imbalance.

- Calcium deficiency: restores serum calcium levels to support neuromuscular function and bone metabolism. - Hypocalcemia: provides rapid intravenous calcium to raise low blood calcium concentrations in acute settings. - Electrolyte replacement: supplies calcium ions as part of comprehensive electrolyte therapy during surgery or critical care.

Calcium chloride dihydrate may be associated with several adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort or burning sensation at the infusion site, usually transient. - Phlebitis: inflammation of the vein used for administration, presenting as redness, swelling, and tenderness. - Hypercalcemia (mild): transient elevation of serum calcium that typically does not produce symptoms. - Nausea: occasional feeling of queasiness or upset stomach during or shortly after infusion.

Serious or Rare Side Effects: - Severe hypercalcemia: marked increase in calcium levels that can cause muscle weakness, confusion, and cardiac arrhythmias. - Cardiac arrhythmias: abnormal heart rhythms, including ventricular tachycardia, that may be life‑threatening. - Tissue necrosis: damage to surrounding tissue if the solution leaks out of the vein (extravasation), leading to ulceration. - Anaphylactic reaction: rare severe allergic response with hives, airway swelling, and hypotension requiring emergency care.

When using Icalziss, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Renal impairment: monitor serum calcium and renal function closely during therapy. - Cardiac disease: avoid rapid infusion in patients with known arrhythmias or heart failure. - Hyperparathyroidism: use with caution as calcium load may exacerbate the condition. - Concurrent calcium products: assess total calcium intake to prevent excess. - Store at ambient temperature: keep in original container, protect from moisture and light.

Calcium chloride dihydrate can interact with certain medications, affecting calcium balance or drug efficacy.

Major Interactions (Avoid): - Vitamin D analogues: increase risk of severe hypercalcemia when combined. - Loop diuretics: may cause rapid shifts in calcium levels, requiring careful monitoring. - Bisphosphonates: calcium supplementation can reduce the drug’s effectiveness on bone resorption.

Moderate Interactions (Monitor Closely): - Magnesium supplements: may interfere with calcium homeostasis and require dose adjustment. - Aluminum‑containing antacids: can bind calcium and reduce its absorption. - ACE inhibitors: monitor blood pressure as calcium infusion may influence vascular tone.